The randomized DSETAMIS (Endoscopic Submucosal Dissection vs Transanal Minimally Invasive Surgery in Early Rectal Neoplasia)-2018 noninferiority trial comparing endoscopic submucosal dissection (ESD) with transanal minimally invasive surgery (TAMIS) for early rectal neoplasms, together with the accompanying editorial proposing that “ESD is no longer the challenger; it is the standard to beat,” calls for a clear methodologic and clinical correction.1,2 The trial is ESD vs TAMIS—not ESD vs transanal endoscopic microsurgery (TEM)— and these platforms are not interchangeable.
The randomized DSETAMIS (Endoscopic Submucosal Dissection vs Transanal Minimally Invasive Surgery in Early Rectal Neoplasia)-2018 noninferiority trial comparing endoscopic submucosal dissection (ESD) with transanal minimally invasive surgery (TAMIS) for early rectal neoplasms, together with the accompanying editorial proposing that “ESD is no longer the challenger; it is the standard to beat,” calls for a clear methodologic and clinical correction.1,2 The trial is ESD vs TAMIS—not ESD vs transanal endoscopic microsurgery (TEM)— and these platforms are not interchangeable.